专业制药公司OptiNose举行了2024年第一季度财报电话会议，分享了积极的财务发展和未来一年的战略计划。首席执行官Ramy Mahmoud博士强调了公司的巨大增长潜力，特别是在XHANCE治疗慢性鼻窦炎方面。OptiNose报告称，XHANCE在2024年第一季度每份处方的净收入显著增加，比2023年第一季度增长63%。该公司还对2024年的收入前景持乐观态度，预计净收入将增长20-34%，预计到2025年销售额将达到至少3亿美元的峰值。此外，OptiNose宣布了一项5500万美元的融资协议，以加强其财务状况，并概述了XHANCE的全面推出计划。
OptiNose报告称，XHANCE的每股净收入增长了63%与2023年第一季度相比。
该公司预计，XHANCE在2024年全年的净收入将增长20-34%。
OptiNose宣布获得5500万美元融资，以加强其财务状况。
XHANCE的全面启动计划包括销售人员参与和培训计划部分。
该公司预计，到2025年，XHANCE的峰值销售额将至少达到3亿美元，并实现正运营收入。
2024年全年净收入预计在8500万美元至9500万美元之间。
2024年的总运营费用预计在9500万美元至1.01亿美元之间。
提高每台印刷机的净收入预计2024年全年的费用将超过230美元。
OptiNose的目标是建立一个盈利的耳鼻喉科和专注于过敏的业务，并扩展到更大的处方店se。
为扩大标签的保险范围建立广泛的模式还为时过早。
该公司目前专注于专业受众，尚未决定初级保健细分市场的报告粒度。
该公司看到了创造股东价值的重大机会。
乐观可能会消失业内人士考虑在未来重新开发新的治疗方法。
预计收入将在2024年第二季度开始增长。
第三方数据提供商可能无法捕获共同支付为0美元的新启动。
每台印刷机的净收入描述受业务行为的影响，而不是直接受标签更改的影响。
该公司正在收集数据，为未来在不同细分市场和促销活动中的努力提供信息响应性部分。
下一个第二季度业绩的电话会议将于8月举行。
OptiNose的战略重点是慢性鼻窦炎治疗，其旗舰产品XHANCE的前景乐观，表明该公司的强劲增长轨迹。每份处方净收入的增加和预期净收入的增长反映了公司成功实施了其业务战略。凭借稳健的上市计划和扩展到初级保健和国际市场的潜力，OptiNose准备增强其市场占有率，为股东和患者提供价值。
OptiNose最近公布的2024年第一季度财报电话会议显示，该公司前景光明，尤其是其XHANCE产品。为了更深入地了解OptiNose的财务状况和市场表现，以下是InvestingPro提供的一些关键指标和见解:
公司过去十二个月的毛利率截至2024年第一季度，OptiNose的使用率达到了令人印象深刻的88.98%，这表明OptiNose在任何时候都是有效的控制与产品生产相关的成本，例如XHANCE。
OptiNose在过去一个月里获得了强劲的回报，股价上涨了35.82%。这可能是投资者信心日益增强的一个迹象对公司战略和市场地位的信心。
尽管过去12个月没有盈利，但OptiNose的流动资产超过了其短期债务，这表明该公司拥有坚实的财务缓冲，可以支持其近期的运营和战略计划。
InvestingPro为OptiNose提供的提示显示，虽然该公司正在迅速烧钱，但其股价往往与市场走势相反。这可能意味着OptiNose的股票可能为投资者的投资组合提供一定程度的多样化。此外，分析师预计该公司今年不会盈利，这是潜在投资者的一个重要考虑因素。
对于那些有兴趣深入了解OptiNose财务和股票表现的人，可以在http://k1.fpubli.cc/file/upload/202405/19/za5uiwrqi1k上获得额外的InvestingPro提示。使用优惠券代码PRONEWS24可以获得一年或两年一次的Pro和Pro+订阅额外10%的折扣，并获得总共8个InvestingPro提示，可以提供进一步的指导和分析。
接线员:您好，谢谢您的等待。欢迎参加OptiNose 2024年第一季度财报电话会议。此时，所有参与者都处于仅听模式。演讲结束后，将有一个问答环节。[接线员说明]请注意，今天的会议正在录音。现在我想把会议交给今天的演讲者，Jonathan Neely，投资者关系副总裁。请继续。
乔纳森·尼利:早上好，感谢大家今天参加我们的节目，我们将回顾OptiNose 2024年第一季度的业绩和未来一年的计划。今天和我在一起的是我们的首席执行官拉米·马哈茂德博士。本次电话会议的幻灯片可以在我们的网站optinose.com的投资者部分查看。在我们开始之前，我想提醒大家，我们这次电话会议的讨论将包括前瞻性陈述。所有非历史事实的陈述均被认定为前瞻性陈述。前瞻性陈述受风险和不确定性影响，可能导致实际结果与此类陈述所示的结果存在重大差异。有关这些因素和前瞻性陈述的其他信息在我们今天发布的收益发布的前瞻性陈述部分的警惕性说明下进行了讨论，在风险因素部分和OptiNose向美国证券交易委员会提交的最新表格10-K和10-Q的其他地方进行了讨论，并在他们的网站SEC .gov和我们的网站optinose.com上提供。请不要过分依赖前瞻性陈述。本次电话会议中的前瞻性陈述仅以本次电话会议的原始日期或该等声明中指明的任何更早日期为准，我们不承担更新或修改任何这些陈述的义务。我们现在先作准备发言，然后进入问答环节。说到这里，我现在把电话交给拉米。
Dr. Ramy Mahmoud: Thank you, Jonathan, and thank you to everyone listening for joining us this morning. We appreciate you joining us for our first quarter 2024 update. Starting on Slide 3. I'll start with a brief outline of what we'll cover during our call today. To start off, I'll review three key takeaways from today's call and discuss our initial plans to reach out to our ENT and allergy specialist physician audience with XHANCE's new clinical profile, including communication of data showing strong efficacy in chronic sinusitis, which our market research indicates a leading driver of prescribing behavior. Next, Jonathan Neely, our VP of Investor Relations and Business Development, will review our first quarter 2024 performance and our financial guidance for full year 2024. Finally, I'll return to review information about our peak net revenue estimates for XHANCE and the profitability targets that we described on our XHANCE chronic sinusitis launch call in April. Then we'll wrap up the call and take your questions. Turning to Slide 4. We'll go into more detail in a moment, but I'd like to highlight three key takeaways from today's presentation. First, I'd like to reiterate the significance of the opportunity in front of us, which we believe has potential to reshape this business in the last three quarters of 2024 and for years into the future. Claims data suggests that chronic sinusitis is currently being diagnosed by health care providers at least 10x more frequently than nasal polyps. Following our national launch meeting, the week of April 8, we have now fully engaged our sales team in our chronic sinusitis launch with training and a full set of materials. As a reminder, our plan is to launch with our current sales force structure armed with a new suite of chronic sinusitis promotional materials, accompanied by digital and nonpersonal promotion efforts based on the new label and with the objective of attaining peak year sales of at least $300 million and producing positive income from operations for full year 2025. Second, thanks to the efforts of our team, we have a significantly stronger base to build on than we did at the start of 2023. When I started as CEO, we implemented an initiative to greatly increase our operating efficiency and to stabilize XHANCE revenue, while preparing our organization to seize the greatly expanded opportunity in chronic sinusitis. We successfully met or exceeded the financial expectations we set for the last five consecutive quarters of revenue achievement, aggressive operating expense reductions and improvements in our average net revenue per prescription. Third, the combination of expanded market opportunity and improved base business fundamentals has set up the opportunity for OptiNose to return to strong growth in 2024. We've now announced our initial guidance for full year 2024 net revenues and total operating expenses. Mindful that the full launch of the ES indication started in mid-April, we expect XHANCE's net revenues to increase by 20% to 34% for full year 2024 compared to full year 2023. We also believe that XHANCE's net revenue growth can be achieved with modest incremental operating expense increases to support promotional efforts while leveraging our existing commercial infrastructure. Turning to Slide 5. Last week, we announced a $55 million registered direct financing, which was led by Nantahala and D.E. Shaw and had participation from both new and existing health care-focused investors. As a result of this funding, OptiNose now has cash and cash equivalents of approximately $100 million. Following on top of the recent approval of the chronic sinusitis indication, this financing is transformative for our company because in the context of our base business plan, we now have sufficient cash runway to operate our business while servicing our debt through 2025, which is when we expect to produce income from operations for the full year. As part of the funding, we also favorably amended the terms of our debt agreement with a waiver of the going concern covenant until the filing of our December 31, 2025 financial statements, which is expected to occur in March of 2026. Additionally, the minimum liquidity covenant will be reduced from $30 million to $20 million following the date of the first quarterly payment to principal, which is due on September 30, 2025. We also extinguished $4.7 million of outstanding amendment and waiver fees, which have now been converted to equity. As a result of this financing and our revised debt agreement, OptiNose is in a greatly strengthened financial position to consider multiple future opportunities for value creation with our initial focus remaining squarely on our XHANCE launch plan. Turning to Slide 7 and our launch plan. In the second quarter of this year, we are leveraging four major tactics to launch XHANCE into this major new market opportunity. These include our sales force, nonpersonal promotion, peer-to-peer education and presence at medical meetings. Let's begin with our 75-person sales organization. In the second quarter, our team plans to reach approximately 7,500 target health care providers and make over 35,000 total sales calls. We're also supplying the field with 50% more XHANCE samples to stimulate additional physician and patient trial. In a highly symptomatic condition like chronic sinusitis, samples can be effective in facilitating new product adoption. It's still very early days for us in the field, but initial feedback has been quite positive. Execution has been strong, and we expect the momentum in XHANCE prescribing to build over time with continued sales force engagement. We are supplementing the field force with nonpersonal promotion targeting a total of 22,000 of the highest potential largely specialty prescribers. These tactics include digital media, search engine marketing and social media. In the second quarter, we plan to generate 1.5 million health care provider impressions and over 50,000 customer engagements using this approach. We're also deploying a peer-to-peer speaker program with approximately 80 specialist prescribers familiar with both the product and the clinical trial data who are available to host educational events for their peers. During the second quarter, we plan to reach over 1,000 health care providers to highlight the new XHANCE clinical profile and discuss unmet need and diagnostic criteria, which are important considerations for facilitating appropriate patient identification in the clinic. Lastly, we're planning a strong presence at medical meetings during the second quarter, including 10 national and 20 regional events for ENTs and allergists. We have a booth where our team can interface with prescribers and are also planning to host promotional events such as product theaters with speakers. These events are aimed at disseminating our message about the recent approval and new clinical trial data, reinforcing the clinical benefits of XHANCE and reinforcing our leadership and visibility in the chronic sinusitis space. Taken together, these four tactical pillars are essential elements of our launch plan. I'll also remind you that we recently implemented hub services intended to increase the service level for prescribers and patients while also resulting in overall improvement in the rate of written prescriptions that are ultimately filled and the rate at which insurance coverage and co-pay support are correctly applied to each prescription. Our generous co-pay support program will continue to facilitate patient starts with many patients being offered $0 co-pays in their first month. Although many of these new initiations are not captured by IQVIA, they can help patients and providers gain personal experience with the benefits of XHANCE even if insurance coverage is still pending. We're also aware that it can often require five to seven calls on new physicians before initiation of product trials and that successful product trials are a precursor for consistent adoption over time. We believe our planned efforts will get the ball rolling and result in gradually accelerating product uptake. All these activities in the context of our preexisting payer access, which includes broad commercial coverage and which we expect to typically adapt to include our new indication over the first few months following approval, are expected to drive an uptick in XHANCE growth this year and ultimately deliver at least $300 million in peak sales in peak year. I would like now to turn the call over to Jonathan Neely to review our financial guidance for full year 2024 and the equity offering we announced on May 9. Jonathan?
Jonathan Neely:谢谢你，Ramy。转到幻灯片9。我们对2020年第一季度的财务业绩感到鼓舞。在收入方面，OptiNose在2024年第一季度确认了1490万美元的XHANCE净收入，与2023年第一季度的1180万美元净收入相比增长了26%。正如我们在上次财报电话会议上所讨论的那样，实力和需求为我们提供了逐步改变的机会，我们-这对盈利能力产生了积极影响。在2023年底和2024年初，我们对共同支付援助计划进行了逐步修订，并实施了新的枢纽服务。这些变化优先考虑增长和有利可图的处方，并减少了无利可图的处方的数量和比例。从XHANCE每份处方的净收入中可以明显看出这一结果。根据从第三方购买的临床处方和库存数据以及我们直接从首选药房网络中心收到的数据，预计XHANCE 2024年第一季度每张处方的平均净收入为每张处方227美元。与2023年第一季度每个处方的估计平均净收入139美元相比，这一数字增长了63%。除了共同支付援助的变化和中心服务的实施之外，我们认为Change Healthcare(纳斯达克股票代码:CHNG)的服务中断，为我们管理XHANCE共同支付支持计划的供应商索赔处理程序，暗示未覆盖的患者可以获得我们的共同支付福利。我们认为这种中断对XHANCE每个处方的净收入产生了有利影响，并预计它将被隔离到2024年第一季度。最后，正如我们之前报道的那样，OptiNose在2024年第一季度确认了2170万美元的SG&A和研发费用。与2023年第一季度2450万美元的支出相比，这一数字约为300万美元，减少了11%。上周，我们宣布了2024年XHANCE全年净收入和2024年全年运营费用的初步财务指导。此外，鉴于2024年第一季度的表现强于预期，我们提高了对2024年全年XHANCE每份处方净收入的预期。首先，对于2024年全年，我们预计总运营费用将在9500万美元至1.01亿美元之间，其中约600万美元预计将用于股票薪酬。其次，鉴于CS市场机会的扩大，我们预计XHANCE的净收入将有强劲增长。我们预计XHANCE 2024年全年的净收入在8500万美元到9500万美元之间。最后，我们现在预计XHANCE在2024年全年每份处方的净收入将超过230美元。此前，我们预计XHANCE在2024年全年每份处方的净收入约为220美元。我想把话筒交给拉米做结束语。Ramy吗?
Dr. Ramy Mahmoud: Thank you, Jonathan. Turning to Slide 13. In April, we provided a financial outlook for XHANCE in chronic sinusitis that we believe we can meet or exceed within our base business. It is important to note that in the context of our base business objectives, although we're treating this as a product launch, in the short term, we're not planning significantly increased investments in our commercial infrastructure. For the time being, we plan to engage a largely specialty physician audience with our current 75 territory size sales team, although we may consider future expansion of our sales organization to further accelerate our launch. Although the size of our sales team is remaining steady, what will be dramatically different is the message we can convey to doctors as we promote XHANCE for a significantly larger population of approximately 3 million patients cared for in our specialty segment. importantly, we believe that a much broader range of physicians commonly make the diagnosis of chronic sinusitis than the diagnosis of nasal polyps. This includes prescribers who are not equipped to routinely perform nasal endoscopy in office, a procedure, which is often relied on to confirm a diagnosis of nasal polyps. With this in mind, we believe we can realistically achieve peak net revenues of at least $300 million and produce positive income from operations for full year 2025. Turning to Slide 14. In addition to the potential within our base business, we believe there's meaningful future potential value to unlock outside of our base business plan, and I'll focus on that topic to wrap up today's call. The first thing I'll highlight is the potential to expand the size of our sales organization by adding up to 40 additional sales territories. Increasing our sales reach to a larger population of specialty prescribers could push our peak year net revenue potential above our initial guidance of at least $300 million, and we will carefully consider if and when this incremental investment is appropriate. Next, we believe our product is well suited to support outreach to a primary care prescribing audience. We could pursue this opportunity, either by adopting alternative selling models like digital promotion or through direct selling partnerships to access an additional 7 million actively diagnosed and treated patients with chronic sinusitis. In future, we could also invest in capital-efficient approaches to activating the 20 million additional patients with chronic sinusitis who are symptomatic, but not actively seeking care each year. based on direct-to-consumer pilot data that we have, we believe the XHANCE product profile is well suited to support strong patient activation. Third, I'd like to note that to date, we have not invested significant energy in establishing international partnerships for XHANCE, but we have maintained patents in select major markets. These represent another potential incremental source of value. Lastly, we aim to leverage our existing infrastructure, particularly our commercial infrastructure to generate synergies by working on additional products. OptiNose is establishing strong infrastructure experience and competencies in what we consider the comparatively blue ocean ENT and allergy specialty space. As we generate income from operations, which we expect for full year '25 and continue to strengthen the organization, OptiNose has potential to become the commercialization or development partner of choice for companies in the specialty space. Collectively, we believe there are significant opportunities ahead to create shareholder value. And when the time is right, we will carefully consider our options and the potential to return to our successful development routes and build a pipeline of new and innovative treatments to address unmet need in our specialty arena. Turning to Slide 15. Before moving to take any questions, I'd like to reiterate the significance of the opportunity in front of us, which we believe has potential to reshape our business starting in the second quarter of this year and for years into the future. We're pleased with our success in executing our prelaunch operating strategy through 2023 in the first quarter of 2024. We achieved greatly increased operating efficiency while stabilizing revenue in the comparatively niche nasal polyp indication, while preserving capital and focusing our organization on preparations to seize the opportunity created by approval of XHANCE as the first prescription treatment for one of the most common diseases diagnosed in adult outpatient medicine. We believe the launch opportunity we are just getting off of the ground, coupled with our recent financing, positions us well to build a profitable ENT and allergy-focused business by accessing greatly expanded net revenue potential through an efficient existing base of commercial capabilities. In addition, we believe the chronic sinusitis indication will facilitate commercial partnerships or other approaches to accessing incremental value in the primary care space that is in addition to what we can access on our own in the specialty segment. With that, I'd like to thank you for your attention and open up the call for Q&A.
接线员:[接线员说明]我们的第一个问题来自湖街资本市场的托马斯·弗拉滕。
托马斯·弗拉滕:我只是想消化一下每份处方平均收入的巨大优势，特别是考虑到Q中关于改变医疗保健潜在的一次性优势的评论。我只是想知道你能否帮我们画出你对每个处方的平均收入的预期——一年内的节奏是怎样的?你是否习惯了第二季度的大幅上涨，但我不确定今年我们是否应该以同样的方式思考?如有任何帮助，我将不胜感激。
乔纳森·尼利:你想继续讲关于医疗改革的部分吗?我来谈谈节奏。
拉米·马哈茂德博士:所以我们相信改变医疗保健有效果。但正如我们在评论中指出的那样，汤姆，这并不是我们在2024年第一季度每份处方的平均净收入高于往年的唯一原因。所以我们确实认为仍然存在季节性趋势，如果你愿意的话，第一季度通常会低于随后的季度。然而，我们所做的是，我们为每个处方的预期平均净收入提供了全年指导，以帮助人们了解我们对今年剩余时间的预期。
乔纳森·尼利:是的。因此，考虑到今年相对于前几年的节奏，我认为我们预计的是，从第一季度到今年剩余时间里，每个处方的收入不会有真正显著的增长。但我们确实相信，我们积极主动地对业务进行改变，我们将在一年的基础上对每个处方的收入产生积极的影响。但我们现在已经将我们的估计从每份处方大约220美元提高到至少或超过230美元。所以我们仍然认为，今年内情况会有所改善。
托马斯·弗拉滕:我在Q中看到的另一件事是，有评论说，有机会获得XHANCE的覆盖生命数量从80%下降到70%。我想知道你能否对此发表评论。
拉米·马哈茂德博士:是的。我认为这更多的是我们衡量方式的结果，而不是覆盖范围变化的结果。如果你误会了，我很抱歉。我们的意图一直都是，或者说我们的期望一直都是我们所覆盖的生命数量不会因为新的指标而发生实质性的变化。我们所期望的是在这些生命中获得覆盖的便利程度上的改善因为我们期望人们受到利用管理的约束，就像事先的授权不再需要只有鼻息肉的适应症，这是一个更难做出的诊断，很少被编码，现在也可以有慢性鼻窦炎的适应症，这在门诊就诊中被广泛编码。
乔纳森·尼利:我认为从历史上看——是的，我认为从历史上看，当我们谈论覆盖的生命百分比或包括XHANCE的计划时，我认为我们历史上只关注商业，但我认为我们已经开始提供一个衡量所有保险计划的指标，无论是商业还是政府。
托马斯·弗拉滕:有道理。最后一个小问题。你发的样品，是30天的剂量吗?或者现在有30天的剂量可用?还是样品中的药物量少了?
拉米·马哈茂德博士:不，我们分发的大多数样本都是特定的样本，没有整整30天。这足以让你开始，并希望给你时间能够从任何药房收到你的处方，包括你可能会访问的邮购。
接线员:下一个问题来自派珀·桑德勒的大卫·阿姆塞勒姆。
斯凯勒:我是斯凯勒，找大卫。你能讲一些趣闻轶事吗?自从品牌扩张以来，你在付费方的前景方面看到了什么?没有鼻息肉的患者获得保险有什么障碍吗?对于Rx的长期净收入，你认为在水标签的背景下它会如何发展?
拉米·马哈茂德博士:斯凯勒，谢谢你的问题。我将从第二个开始。至于每份处方的平均净收入，我不认为这是标签变化的结果。它对我们在共同支付支持项目和其他商业活动中所做的改变非常敏感，但对药物处方的适应症并没有真正的影响。关于保险范围的轶事，我能和你们分享的是，事实上，对于我们成立以来建立的广泛模式来说，仅仅是轶事还为时过早。只是没有足够的时间。当然，有成千上万种不同的保险计划。我不能跟他们每个人都说。我可以告诉你，我们已经得到了具体的轶事报道，新适应症被添加到先前的授权表格中，正如我们之前讨论过的那样，我们预计在批准后的几个月里会发生什么——我不知道由于新适应症而发生的任何不良反应。我们确实希望逐步看到新的适应症加入到目前的事先批准标准中。
Schuyler van den Broek:明白了。这是有帮助的。然后再来一个。关于销售队伍，我想你提到了未来的潜在扩张。你能谈谈是什么因素造成的吗?
拉米·马哈茂德博士:是的。我认为我们期待看到我们最初的促销活动的结果，我们正在密切关注它，进行相当密集的分析。当我们更好地了解我们所产生的提升以及产生最佳投资回报率的驱动因素时，我们将使用这些信息来告知我们在促销活动中所做的任何改变的幅度和时间。
接线员:[接线员说明]我们的下一个问题来自Jefferies的Glen Santangelo。
Glen Santangelo: Ramy，我还想跟进一下——就你所看到的付费覆盖范围而言。听起来你说你逐渐看到新的适应症增加了。你能告诉我们大概需要多长时间吗?因为我认为这将是一个相对快速的过程，考虑到付款人对产品的熟悉程度。我试着把它放在这个背景中——与24财年的全年指导以及可能在这个时间点上领导商业基础设施的决定联系起来。我的意思是，我猜我们都在试图弄清楚的是其中的节奏，那些付款人合同可以修改，我们什么时候应该开始期待收入方面的一些加速?
拉米·马哈茂德博士:格伦，谢谢你的问题。这可能听起来很明显，但我们并不能直接控制各种保险计划中这些变化的速度。有一小部分主要的药品福利管理机构和保险公司，但是有成千上万的保险计划。我有一些已经做出改变的具体例子，还有一些还没有做出改变的例子。所以，我们估计这需要一些计划，几个星期;在一些计划中，这些变化需要几个月的时间才能最终推出。这是我们自己需要注意的事情之一。我们试图对保险公司保持透明，以便每个人都能充分意识到即将到来的新迹象。我们已经尽我们所能帮助他们做出这些改变。但归根结底，这并不是我们能直接控制的。你问我们在收入上开始有所不同。我们试图给你们一些指引，我认为这些指引清楚地表明，我们预计本季度的收入会增加。因此，在第二季度，我们预计收入将开始增长，并预计在今年剩余时间内增长，最终在2024年达到8500万至9500万美元，这比2023年要高得多。
乔纳森·尼利:格伦，你确实问了一个问题——你问了一个关于修改协议的节奏的问题。我认为这并不是对协议修改的节奏。我认为这更多的是付款人的节奏，这反映了合同在很大程度上考虑了扩大标签，他们考虑回扣，每当产品因fda批准的标签上的适应症而报销时。所以我不认为这是一个合同讨论。我认为更重要的是让保险公司反映标签和产品的状态，让他们的业务流程反映这些。这不是重新谈判。好吧。
格伦·桑坦杰洛:也许再给我两杯就行了，然后我就走。本季度的脚本总数，根据每个脚本的平均收益来看，似乎下降了相当多。我想知道你能否对此发表评论。其次，你的最高销售额是3亿美元，拉米或约翰，你能不能在这个数字背后再多讲一些内容?你是如何得出这个数字的?我们应该如何从一个剧本和每个剧本的平均收益角度来看待这个数字?
乔纳森·尼利:当然。我的意思是，就季度处方而言，我认为正如我们所描述的，我们在2023年底和2024年初对共同支付援助计划进行了一些改变，我们认为这让我们专注于增长我们业务的盈利部分，减少了无利可图的处方的数量和比例。因此，如果你看一下处方，你会发现，与去年同期相比，下降了近23%。但重要的是，我们的业务中存在一些处方，这些处方不再被填补，从而提高了我们的收入表现。所以，再一次，回到我们在这里的财务表现，收入同比增长26%。
拉米·马哈茂德博士:我再补充一点，因为你可能在之前的评论中忽略了这一点，我们正在减少无利可图甚至是负收益的处方数量。我们也专注于盈利处方的增长。所以在管理业务方面，我们要做的不是增加处方总量，而是增加利润。我要提的另一件事，只是提醒一下，外部第三方供应商对处方的跟踪是不完善的。它总是不完美的，随着时间的推移，它对实际数字的反映也会有所不同。但我在之前的评论中强调的一点是，那些不成比例地试图推动新发布的新项目，那些共同支付为0美元的新项目可能根本不会被第三方数据提供商捕获。所以你是看不见的。
乔纳森·尼利:我想对今年的指南以及对处方增长和每份处方收入增长的影响做最后的评论。我认为，鉴于我们已经提供了收入的范围和下限，如果你愿意的话，每个处方的收入，我认为如果你反向计算，你可以得出，我们预计处方和收入都将同比增长，收入也将同比增长，每个处方的收入也将同比增长。
拉米·马哈茂德博士:格伦，我要补充的最后一件事是你问了关于3亿美元的问题。我的观点是，让我们从2024年走向高峰的增长是产品使用的增长。每个处方的平均净收入并没有真正有意义的增量增长。在过去的，我不知道，大概九个月左右的时间里，有很多杠杆可以撬动。但在未来，主要的增长将来自于对该产品的吸收。
主持人:下一个问题来自H.C. Wainwright的马修·考菲尔德。
马修·考菲尔德:恭喜到目前为止发射成功。因此，感谢针对过敏症专科医生和耳鼻喉科的专科医生的努力，您是否计划分享一些细节，比如，未来几个季度可能来自初级保健部门的处方数量?那么这可能会对未来的销售工作产生什么影响，大概，初级保健可以开处方，但不是当前的重点?
拉米·马哈茂德博士:是的。马特，我们还没有就如何报告未来增长的指标做出决定。但就像你说的。我们现在的努力主要集中在专业用户身上。我们的大学里确实有一些初级保健医生，人数不多。我们的非个人促销活动确实有更多的受众，当然，我们将收集有关促销反应和吸收的数据，这些数据是根据产品在不同细分市场的使用方式收集的，我们将利用这些数据为我们未来的努力提供信息。但是马特，我不想设定一个期望，至少在不久的将来，我们会通过开具专业处方来具体报告任何事情……
马修·考菲尔德:好的。很好。非常有帮助，非常兴奋看到发射，祝贺伙计们。
拉米·马哈茂德博士:再次感谢你，马特。
接线员:我现在没有问题了。现在请首席执行官拉米·马哈茂德致闭幕词。
拉米·马哈茂德博士:很好。我想感谢大家的到来。是的，今天早上。我感谢你的关注和帮助，我希望你能分享我们的兴奋，因为今天的公司与一年前或更多年前相比有了很大的不同。在过去的几个月里，我们获得了新的批准和新的融资，我们觉得我们处于一个更好的位置，可以真正创造股东价值，帮助数百万患有这种疾病的人，他们以前没有其他治疗方法。我们期待着在8月份再次与您分享我们的第二季度业绩。
接线员:今天的电话会议到此结束。谢谢你的参与。您现在可以断开连接。
本文是在人工智能的支持下生成的，并由编辑审阅。欲了解更多信息，请参阅我们的T&C。
